<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578823</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1071</org_study_id>
    <nct_id>NCT02578823</nct_id>
  </id_info>
  <brief_title>Targeted Temperature Management After In-Hospital Cardiac Arrest</brief_title>
  <acronym>TTM36-IHCA</acronym>
  <official_title>Targeted Temperature Management at 36℃ After In-Hospital Cardiac Arrest Trial(TTM36-IHCA Trial): An Investigator-Initiated, Single-Center, Randomized, Controlled, Assessor-Blinded, Pilot Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether targeted temperature management at&#xD;
      36.0˚C(TTM-36) in patients who remain unconscious after resuscitation from in-hospital&#xD;
      cardiac arrest(IHCA) will reduce death and disability compared with fever control. For this&#xD;
      purpose, the current pilot study will be undertaken to establish the feasibility, safety, and&#xD;
      surrogate outcomes of hypoxic-ischemic brain injury in 60 patients who remain unconscious&#xD;
      after resuscitation from IHCA.&#xD;
&#xD;
      Eligible patients will be randomly assigned in a 2:1 ratio to either TTM-36(n=40) or&#xD;
      conventional treatment group(n=20). Randomization will be performed with stratification&#xD;
      according to initial rhythm (shockable vs. non-shockable).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination of death and poor neurological function defined as a Cerebral Performance Category (CPC) score 3 to 5 at 180 days</measure>
    <time_frame>day 180</time_frame>
    <description>Efficacy of targeted temperature management at 36.0℃(TTM-36) will be assessed by using Cerebral Performance Category(CPC) score. CPC score is the surrogate outcome for hypoxic-ischemic brain injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The CPC score 3 to 5 at day 7 and at day 30</measure>
    <time_frame>day 7, day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The highest levels of serum neuron specific enolase(NSE) during the first 5 days</measure>
    <time_frame>up to day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unfavorable Electroencephalography(EEG) patterns</measure>
    <time_frame>day 0, day 4</time_frame>
    <description>Generalized suppression(≤20 μV)&#xD;
Burst-suppression with generalized epileptiform activity&#xD;
Generalized periodic epileptiform discharges on a flat background&#xD;
No EEG reactivity&#xD;
Electrographical seizures&#xD;
Electrographical status epilepticus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of magnetic resonance imaging(MRI) at day 4</measure>
    <time_frame>day 4</time_frame>
    <description>Total magnetic resonance imaging(MRI) scores&#xD;
The percentage of brain volume with Afferent Diffusion Coefficient(ADC) values &lt; 650 x 10^-6mm^2/sec&#xD;
The percentage of brain volume with ADC values &lt; 450 x 10^-6mm^2/sec&#xD;
Number of cerebral microbleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS) score 4 to 6 at day 30 and at Day 180</measure>
    <time_frame>day 30, day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at day 30, at Day 180</measure>
    <time_frame>up to day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoclonic or tonic-clonic seizures or status epilepticus(SE)</measure>
    <time_frame>up to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological status estimated by the Seoul Neurosychological Screeninig Battery (SNSB) 2nd ed.</measure>
    <time_frame>day 180</time_frame>
    <description>Attention: Digit span (forward), digit span (backward)&#xD;
Language &amp; related function: Spontaneous speech, comprehension, repetition, reading, writing, finger naming, body part identification, right-left orientation, calculation; BNT (Boston Naming Test)&#xD;
Visuospatial: RCFT (Rey Complex Figure Test) copy score&#xD;
Memory: SVLT (Seoul Verbal Learning Test), RCFT (immediate recall, delayed recall, recognition)&#xD;
Frontal &amp; executive function: COWAT (Controlled Oral Word Association Test), CWST (Color Word Stroop Test), DSC (Digit Symbol Coding), TMT (Trail making test)&#xD;
General cognitive index: MMSE (Mini Mental State Examination), CDR (Clinical Dementia Rating), GDS (Global Deterioration Scale)&#xD;
Activities of daily living (ADL): Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other neurological evaluations</measure>
    <time_frame>day 180</time_frame>
    <description>Depression: BDI (Beck Depression Inventory)&#xD;
Quality of life: SF-36 (Short-Form 36-item Health Survey)&#xD;
Activities of daily life: S-IADL (Seoul-Instrumental Activities of Daily Living)&#xD;
Psychiatric symptoms: NPI (Neuropsychiatric Inventory)&#xD;
Cognition: IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)&#xD;
Parkinsonism: UPDRS (Unified Parkinson's Disease Rating Scale)&#xD;
Ataxia: ICARS (International Cooperative Ataxia Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of follow-up MRI</measure>
    <time_frame>day 30 &amp; day 180</time_frame>
    <description>Resting state functional MRI: Connectivity strength, proportional increase of connectivity strength on resting state&#xD;
Diffusion tensor imaging: Global mean diffusivity, gray matter mean diffusivity, white matter mean diffusivity , mean fractional anisotropy, proportional increase of white matter global fractional anisotropy, proportional increase of white matter global mean diffusivity&#xD;
High resolution T1-weighted imaging for MRI volumetric: Mean volume of the brain, mean volume of the gray matter of the brain, mean volume of the white matter of the brain, proportional increase of mean volume of the brain, proportional increase of mean volume of the gray matter, proportional increase of mean volume of the white matter&#xD;
Susceptibility-weighted imaging: Number of cerebral microbleeds</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of the targeted temperature management at 36.0℃(TTM-36)</measure>
    <time_frame>up to day 7</time_frame>
    <description>Safety will be assessed by the composite measurement below everyday during the first 7 days after cardiac arrest.&#xD;
Cardiac arrest after randomization&#xD;
Arrhythmia(ventricular fibrillation, ventricular tachycardia, atrial fibrillation, atrial flutter, tachycardia &gt;130/min lasting more than 1 hour, and bradycardia &lt;40/min lasting more than 1 hour)&#xD;
Pneumonia(pulmonary infiltration on the chest radiography and 2 or more of fever, leukocytosis, and purulent tracheobronchial secretions)&#xD;
Septic shock(sepsis-induced hypotension persisting despite adequate fluid resuscitation)&#xD;
Culture-proven infection&#xD;
Major bleeding(bleeding requiring more than 2 units of packed red blood cell over 2 hours, bleeding causing fatality, and symptomatic bleeding in critical organs)&#xD;
Shivering(the Bedside Shivering Assessment Scale 2-3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Feasibility</measure>
    <time_frame>up to day 180</time_frame>
    <description>2.5 subjects per month can be recruited&#xD;
At least 50% of all eligible patients can be recruited&#xD;
No more than 10% of all recruited subjects cross over from one modality to the other&#xD;
Complete follow-up in at least 90% of all recruited subjects</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>TTM-36</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.&#xD;
After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).&#xD;
A total of 40 participants will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).&#xD;
A total of 20 participants will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arctic Sun®</intervention_name>
    <description>Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).</description>
    <arm_group_label>TTM-36</arm_group_label>
    <other_name>Temperature Management System Model 5000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arcticgel™</intervention_name>
    <arm_group_label>TTM-36</arm_group_label>
    <other_name>Hydrogel Coated Pad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional antipyretic treatment</intervention_name>
    <description>Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.</description>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_label>TTM-36</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  In-hospital cardiac arrest requiring chest compression for &gt; 2 minutes&#xD;
&#xD;
          -  Sustained restoration of spontaneous circulation(ROSC) for &gt; 20 minutes after&#xD;
             cardiopulmonary resuscitation(CPR)&#xD;
&#xD;
          -  Unresponsive state(lack of meaningful response to verbal commands) for &gt; 20 minutes&#xD;
             after sustained ROSC&#xD;
&#xD;
          -  Informed consents from a patient's family member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unavailable TTM within 2 hours after ROSC&#xD;
&#xD;
          -  CPR duration &gt; 30 minutes&#xD;
&#xD;
          -  Unwitnessed arrest with initial rhythm asystole&#xD;
&#xD;
          -  Under or planned for extracorporeal membrane oxygenation(ECMO)&#xD;
&#xD;
          -  Initial body temperature &lt; 33 °C&#xD;
&#xD;
          -  Preexisting terminal illness with life expectancy &lt;6 months&#xD;
&#xD;
          -  Pre-admission CPC score of 3-5&#xD;
&#xD;
          -  Pre-admission mRS score 4-6&#xD;
&#xD;
          -  Unresponsive(stupor or coma) before cardiac arrest&#xD;
&#xD;
          -  Suspected or confirmed cause of cardiac arrest is diseases of the central nervous&#xD;
             system, such as stroke, brain tumor, or amyotrophic lateral sclerosis&#xD;
&#xD;
          -  Any condition in which direct skin surface cooling would be contraindicated, such as&#xD;
             large burns, unhealed surgical wounds, decubitus ulcers, cellulitis, or other&#xD;
             conditions with disrupted skin integrity&#xD;
&#xD;
          -  Active massive bleeding&#xD;
&#xD;
          -  Major surgery within last 48 hours&#xD;
&#xD;
          -  Cardiothoracic surgery within 14 days&#xD;
&#xD;
          -  Planned surgery within next 72 hours after ROSC&#xD;
&#xD;
          -  Enrolled in other clinical trials&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Do-not-resuscitate(DNR) state&#xD;
&#xD;
          -  Patients whose family or treating physicians refuse to join this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Beom Jeon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Beom Jeon, Dr</last_name>
    <phone>82-2-3010-3440</phone>
    <email>sbjeonmd@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Beom Jeon, Dr</last_name>
      <phone>82-2-3010-3440</phone>
      <email>sbjeonmd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sang-Beom Jeon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Targeted Temperature Management(TTM)</keyword>
  <keyword>in-hospital cardiac arrest(IHCA)</keyword>
  <keyword>restoration of spontaneous circulation(ROSC)</keyword>
  <keyword>unconsciousness</keyword>
  <keyword>brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipyretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

